Lexaria BioscienceLEXX
13F holders, Q4 2025 (December 31)21holders −4
2new positions
6sold out
1famous investor
$0.62avg. 13F price*
At the end of Q4 2025, 21 institutions reported holding Lexaria Bioscience Corp. (LEXX) in their 13F filings, down 4 from Q3 2025. 2 opened new positions and 6 sold out. The largest holders were Invenomic Capital Management LP ($291K), UBS Group AG ($223K) and Vanguard Group Inc. ($160K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Lexaria Bioscience Corp.
- CUSIP
- 52886N406
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $126 |
| Exits | 6 | $458K |
All 13F filers, Q3 2025 → Q4 2025: 479,117 shares bought and 495,237 shares sold, net −16,120 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Invenomic Capital Management LP | 0.01% | Reduce -1.3% | 470,915 | $291K |
| UBS Group AG | 0.00% | Add +4995.9% | 361,300 | $223K |
| Vanguard Group Inc. | 0.00% | No change | 258,816 | $160K |
| Geode Capital Management, LLC | 0.00% | Add +25.7% | 219,718 | $136K |
| Toronto Dominion Bank | 0.00% | No change | 140,013 | $86K |
| Byrne Asset Management LLC | 0.04% | Add +236.8% | 105,500 | $65K |
| State Street Corp. | 0.00% | No change | 39,301 | $24K |
| BlackRock, Inc. | 0.00% | No change | 27,445 | $17K |
| Krilogy Financial LLC | 0.00% | No change | 19,653 | $16K |
| Northern Trust Corp. | 0.00% | No change | 18,389 | $11K |
| Renaissance Technologies | 0.00% | Add +54.5% | 15,600 | $10K |
| Bank of Montreal | 0.00% | Add +0.4% | 14,083 | $9K |
| Royal Bank of Canada | 0.00% | No change | 7,283 | $4K |
| Osaic Holdings, Inc. | 0.00% | Add +0.2% | 2,195 | $1K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 382 | $233 |
| Bank of America Corp. | 0.00% | Add +17.3% | 203 | $126 |
| MAI Capital Management | 0.00% | New | 200 | $124 |
| Farther Finance Advisors, LLC | 0.00% | No change | 166 | $102 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -99.1% | 32 | $20 |
| Gables Capital Management Inc. | 0.00% | No change | 13 | $8 |
| Morgan Stanley | 0.00% | New | 3 | $2 |
"% of holder's portfolio" is LEXX's weight in each manager's 13F, not the share of Lexaria Bioscience Corp. the manager owns.